Evotec (Germany) has launched a spin-off, Topas Therapeutics, to create nanoparticle-based therapeutics to treat immunological disorders.
After starting a collaboration for microbiome-related diseases and entering the immuno-oncology field, Evotec is creating a spin-off dedicated to autoimmune diseases. This new biotech, Topas Therapeutics, is based on a technology that induces liver tolerance to specific antigens.
This platform could be used to create breakthrough therapies for a range of autoimmune and inflammatory diseases. These include, for example, rheumatoid arthritis and Crohn’s disease, so it’s an area with high unmet medical needs, and potentially very profitable.
The technology was originally developed at the University Medical Center Hamburg-Eppendorf (UKE) and resulted in a patent and several publications, including the Journal of Immunology and the Journal of Hepatology. Evotec ended up with the exclusive license for this platform via the acquisition in 2014 of Bionamics, a technology transfer company that joined Evotec’s own program, EVT Innovate.